JP2021525549A5 - - Google Patents

Info

Publication number
JP2021525549A5
JP2021525549A5 JP2021516553A JP2021516553A JP2021525549A5 JP 2021525549 A5 JP2021525549 A5 JP 2021525549A5 JP 2021516553 A JP2021516553 A JP 2021516553A JP 2021516553 A JP2021516553 A JP 2021516553A JP 2021525549 A5 JP2021525549 A5 JP 2021525549A5
Authority
JP
Japan
Prior art keywords
nucleic acid
target
tumor
acid molecule
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021516553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525549A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034229 external-priority patent/WO2019227106A1/en
Publication of JP2021525549A publication Critical patent/JP2021525549A/ja
Publication of JP2021525549A5 publication Critical patent/JP2021525549A5/ja
Priority to JP2024073051A priority Critical patent/JP2024091964A/ja
Pending legal-status Critical Current

Links

JP2021516553A 2018-05-25 2019-05-28 腫瘍特異的ネオ抗原およびその使用方法 Pending JP2021525549A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024073051A JP2024091964A (ja) 2018-05-25 2024-04-26 腫瘍特異的ネオ抗原およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676563P 2018-05-25 2018-05-25
US62/676,563 2018-05-25
PCT/US2019/034229 WO2019227106A1 (en) 2018-05-25 2019-05-28 Tumor-specific neoantigens and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024073051A Division JP2024091964A (ja) 2018-05-25 2024-04-26 腫瘍特異的ネオ抗原およびその使用方法

Publications (2)

Publication Number Publication Date
JP2021525549A JP2021525549A (ja) 2021-09-27
JP2021525549A5 true JP2021525549A5 (enExample) 2022-06-06

Family

ID=68616499

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516553A Pending JP2021525549A (ja) 2018-05-25 2019-05-28 腫瘍特異的ネオ抗原およびその使用方法
JP2024073051A Pending JP2024091964A (ja) 2018-05-25 2024-04-26 腫瘍特異的ネオ抗原およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024073051A Pending JP2024091964A (ja) 2018-05-25 2024-04-26 腫瘍特異的ネオ抗原およびその使用方法

Country Status (8)

Country Link
US (2) US12528848B2 (enExample)
EP (1) EP3801597A4 (enExample)
JP (2) JP2021525549A (enExample)
KR (1) KR20210018321A (enExample)
CN (1) CN112261947A (enExample)
CA (1) CA3100974A1 (enExample)
MX (1) MX2020012649A (enExample)
WO (1) WO2019227106A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
IT201900016718A1 (it) * 2019-09-19 2021-03-19 Takis S R L Combinazione di agenti immunomodulatori con neoantigeni tumore-specifici per l’uso nella prevenzione e nel trattamento dei tumori.
CN112501201A (zh) * 2021-02-07 2021-03-16 无锡市人民医院 一种用于治疗非小细胞肺癌的rna疫苗及其构建方法
AU2023269389A1 (en) * 2022-05-10 2024-12-19 Geneos Therapeutics, Inc. Individualized cancer epitopes and methods of using the same
WO2023220661A1 (en) * 2022-05-10 2023-11-16 Geneos Therapeutics, Inc. Vaccines and methods of using the same to treat wnt-related cancer
US20260174837A1 (en) * 2022-11-07 2026-06-25 The Wistar Institute Of Anatomy And Biology Compositions comprising neoantigens and methods of enhancing anti-pd1 therapy
CN116966105B (zh) * 2023-04-20 2025-12-19 合肥核信生物科技有限责任公司 促进皮肤细胞胶原蛋白生成的小分子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212000B2 (en) 1970-02-11 2012-07-03 Immatics Biotechnologies Gmbh Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
WO2008134878A1 (en) * 2007-05-04 2008-11-13 University Health Network Compositions and methods for cancer treatment
US20090041792A1 (en) 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same
US9115402B2 (en) * 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
CN103068846B9 (zh) * 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
CN103160473B (zh) * 2011-12-13 2014-08-20 北京微谷生物医药有限公司 用于拯救麻疹病毒的组合物、试剂盒、用途及方法
EP3520810A3 (en) * 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
MX428954B (es) * 2013-03-15 2025-11-13 Univ Pennsylvania Vacunación mejorada contra la hormona liberadora de la hormona de crecimiento (ghrh) humana.
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US9907844B2 (en) 2013-12-11 2018-03-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
JP7060324B2 (ja) * 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
CA2961179A1 (en) 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
JP6913032B2 (ja) * 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
EP3328394A4 (en) * 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
WO2017083750A1 (en) * 2015-11-11 2017-05-18 Intrexon Corporation Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
WO2017118702A1 (en) 2016-01-08 2017-07-13 Vaccibody As Neoepitope rna cancer vaccine
WO2017139498A1 (en) * 2016-02-09 2017-08-17 Cour Pharmaceuticals Development Company Inc. Timps encapsulating japanese cedar pollen epitopes
WO2017152042A2 (en) 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
JP2019513021A (ja) * 2016-03-24 2019-05-23 ナントセル，インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
WO2017192924A1 (en) * 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
CA3052255A1 (en) * 2017-02-01 2018-08-09 Modernatx, Inc. Rna cancer vaccines
EP3773649A4 (en) * 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE

Similar Documents

Publication Publication Date Title
JP2021501572A5 (enExample)
JP2025071108A (ja) Ｒｎａがんワクチン
CA2965033C (en) Methods and compositions for diagnosis and treatment of glioblastoma
JP2021518162A5 (enExample)
JP2021518161A5 (enExample)
JP2021518160A5 (enExample)
US12544433B2 (en) Melanoma canine vaccine compositions and methods of use thereof
JP2021532122A (ja) 癌のための個別化ワクチン
JP2025500926A5 (enExample)
JP2024542126A (ja) 自己増幅ｒｎａ組成物及びその使用方法
CN101275147B (zh) 一种人分化抑制因子3表达载体、融合蛋白及其制备方法
CN119770633A (zh) 一种改进型多肽肿瘤疫苗组成与应用
CN119638850A (zh) 双特异性细胞因子融合蛋白及其应用
US20240317831A1 (en) Nk cell engager molecules and methods of use
CN118909138A (zh) 一种肿瘤疫苗及其应用
US8207141B2 (en) Plasmids coding for p185neu protein sequence variants and therapeutic uses thereof
CN101948544B (zh) FAT10基因siRNA重组模拟病毒及其制备方法和应用
JP2024534442A (ja) ネオ抗原アジュバント及び維持療法
CA3183322A1 (en) Methods of determining responsiveness to cancer immunotherapy
CN120590547B (zh) 通用型mRNA肿瘤疫苗及其制备方法和用途
HK40130852A (en) Universal mrna tumor vaccine and preparation method and use thereof
WO2025101551A1 (en) Prostate-specific membrane antigen (psma)-binding peptides and method of use
CN121873266A (zh) 一种增强肿瘤疫苗免疫原性的嵌合多肽及其制备方法和用途
CN118251233A (zh) 一种包含由双链dna库产生的rna库的rna疫苗
CN117924487A (zh) 一种由羊驼重链抗体可变区组成的特异性结合lag3蛋白的纳米抗体及其应用